clenbuterol has been researched along with Chronic Disease in 14 studies
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-one patients with chronic bronchitis and reversible airway obstruction participated in two single-blind, cross-over, placebo-controlled studies in inhaled clenbuterol - a new bronchodilator - and salbutamol." | 9.05 | A comparison between inhaled clenbuterol and salbutamol in chronic bronchitis with reversible airway obstruction. ( Baronti, A; Grieco, A; Vibelli, C, 1980) |
| "Clenbuterol was well tolerated and led to a significant increase in both lean mass and the lean/fat ratio." | 6.73 | Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. ( George, I; Kamalakkannan, G; LaManca, J; Mancini, DM; Maybaum, S; McLaughlin, BT; Petrilli, CM; Shane, E, 2008) |
| "Twenty-one patients with chronic bronchitis and reversible airway obstruction participated in two single-blind, cross-over, placebo-controlled studies in inhaled clenbuterol - a new bronchodilator - and salbutamol." | 5.05 | A comparison between inhaled clenbuterol and salbutamol in chronic bronchitis with reversible airway obstruction. ( Baronti, A; Grieco, A; Vibelli, C, 1980) |
| "A new oral bronchodilator, NAB 365 (clenbuterol), at doses of 10, 20, 30 and 40 microgram, was studied in a double-blind placebo-controlled incomplete cross-over study in 10 patients suffering from chronic bronchitis who had reversible airway obstruction." | 5.04 | Dose-response study of a new oral bronchodilator, NAB 365 (clenbuterol). ( Brusasco, V; Chierichetti, S; Ramoino, R; Vibelli, C, 1978) |
| "Clenbuterol was well tolerated and led to a significant increase in both lean mass and the lean/fat ratio." | 2.73 | Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. ( George, I; Kamalakkannan, G; LaManca, J; Mancini, DM; Maybaum, S; McLaughlin, BT; Petrilli, CM; Shane, E, 2008) |
| "Treatment with clenbuterol caused changes only in calves with subacute bronchopneumonia; in these animals it decreased the total pulmonary resistance, the viscous work per litre and the peak to peak changes in transpulmonary pressure." | 1.27 | The effects of clenbuterol hydrochloride on the pulmonary function of calves with subacute and chronic bronchopneumonia. ( Hajer, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (64.29) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujimura, M | 2 |
| Kamalakkannan, G | 1 |
| Petrilli, CM | 1 |
| George, I | 1 |
| LaManca, J | 1 |
| McLaughlin, BT | 1 |
| Shane, E | 1 |
| Mancini, DM | 1 |
| Maybaum, S | 1 |
| Kawakami, Y | 1 |
| Král, B | 1 |
| Jirkal, J | 1 |
| Eliás, J | 1 |
| Ilnerová, A | 1 |
| Dolezalová, K | 1 |
| Tilser, P | 1 |
| Baronti, A | 2 |
| Grieco, A | 1 |
| Vibelli, C | 3 |
| Kamio, Y | 1 |
| Hashimoto, T | 1 |
| Matsuda, T | 1 |
| Chan, TY | 1 |
| Rensch, H | 1 |
| Renovanz, HD | 1 |
| Cummiskey, J | 1 |
| Keelan, P | 1 |
| Gray, P | 1 |
| Cox, GA | 1 |
| Griceo, A | 1 |
| Brusasco, V | 1 |
| Chierichetti, S | 1 |
| Ramoino, R | 1 |
| Dorow, P | 1 |
| Su, WJ | 1 |
| Perng, RP | 1 |
| Hajer, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy[NCT01942590] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 18
| Intervention | meters (Mean) |
|---|---|
| Clenbuterol | 18.09 |
| Placebo Comparator | 6.878 |
Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 52
| Intervention | meters (Mean) |
|---|---|
| Clenbuterol | 16.42 |
| Placebo Comparator | -18.13 |
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 18
| Intervention | change in FVC measured as % expected (Mean) |
|---|---|
| Clenbuterol | 1.575 |
| Placebo Comparator | 2.825 |
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 52
| Intervention | change in FVC measured as % expected (Mean) |
|---|---|
| Clenbuterol | -5.738 |
| Placebo Comparator | 7.775 |
(NCT01942590)
Timeframe: Baseline, Week 52
| Intervention | mmol/mol CN (Mean) |
|---|---|
| Clenbuterol | -1.1 |
| Placebo Comparator | -1.667 |
The Glc4 biomarker is measured in urine and correlates with muscle glycogen content. It is a noninvasive measurement that serves as a biomarker for Pompe disease. (NCT01942590)
Timeframe: Baseline, Week 18
| Intervention | mmol/mol CN (Mean) |
|---|---|
| Clenbuterol | -1.733 |
| Placebo Comparator | 0.0667 |
Liver toxicity, as defined by a >3x increase in AST or ALT from the respective baseline values and/or an increase in direct, indirect or total bilirubin of >3x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52
| Intervention | participants (Number) |
|---|---|
| Clenbuterol | 0 |
| Placebo Comparator | 0 |
Worsening muscle involvement, as defined by >3x increase in CK from baseline that is >2x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52
| Intervention | participants (Number) |
|---|---|
| Clenbuterol | 1 |
| Placebo Comparator | 0 |
The GSGC is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 4 components: Gait, Climbing Stairs, Gower's Manuever, Arising From a Chair. Lowest score 4 = normal muscle function, highest score 27 = unable to perform motor function tests. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 17 | 15.14 | 13.8 |
| Placebo Comparator | 7.5 | 6.5 | 6.5 |
The Late-Life Function & Disability Instrument (Late-Life FDI) is an evaluative outcome instrument for community-dwelling older adults. Highest score 240 = normal function and no disability, lowest score 0 = low levels of frequency of participating in life tasks. (NCT01942590)
Timeframe: Baseline, Week 18, Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 103.75 | 106.7 | 112.5 |
MEP reflects the strength of the abdominal muscles and other expiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | percentage of MEP (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 40.4 | 40 | 53.9 |
| Placebo Comparator | 62.8 | 83.3 | 49.2 |
MIP is a measurement of inspiratory muscle weakness, including weakness of the diaphragm. MIP is decreased in Pompe disease and reflects weakness of respiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | percentage of MIP (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 56.3 | 47.4 | 68.5 |
| Placebo Comparator | 96.8 | 83.8 | 104.6 |
The QMFT is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 16 motor function tests. Lowest score 0 = unable to perform motor function tests, highest score 64 = normal muscle function. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 35 | 40.6 | 46.5 |
| Placebo Comparator | 53.75 | 54.75 | 56.25 |
3 reviews available for clenbuterol and Chronic Disease
| Article | Year |
|---|---|
[Causes of prolonged and chronic cough].
Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Chronic Disease; Clenbuterol; Cough; Dr | 2008 |
Food-borne clenbuterol may have potential for cardiovascular effects with chronic exposure (commentary).
Topics: Adrenergic beta-Agonists; Animals; Chronic Disease; Clenbuterol; Food Contamination; Hemodynamics; H | 2001 |
[Clenbuterol: review of a new broncholytic agent].
Topics: Bronchi; Chronic Disease; Clenbuterol; Ethanolamines; Humans; Lung Diseases, Obstructive | 1977 |
6 trials available for clenbuterol and Chronic Disease
| Article | Year |
|---|---|
Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure.
Topics: Adrenergic beta-Agonists; Adult; Body Composition; Chronic Disease; Clenbuterol; Double-Blind Method | 2008 |
First clinical studies on mabuterol. A summarizing report.
Topics: Adrenergic beta-Antagonists; Adult; Asthma; Bronchodilator Agents; Cardiovascular System; Chronic Di | 1984 |
A comparison between inhaled clenbuterol and salbutamol in chronic bronchitis with reversible airway obstruction.
Topics: Aerosols; Aged; Airway Obstruction; Albuterol; Bronchitis; Chronic Disease; Clenbuterol; Clinical Tr | 1980 |
Comparison of NAB 365 and salbutamol tablets in chronic bronchitis and asthma.
Topics: Adult; Aged; Albuterol; Asthma; Bronchitis; Chronic Disease; Clenbuterol; Clinical Trials as Topic; | 1978 |
Study of a new oral beta-adrenergic drug, clenbuterol, in patients with chronic bronchitis.
Topics: Aged; Bronchitis; Bronchodilator Agents; Chronic Disease; Clenbuterol; Clinical Trials as Topic; Dou | 1978 |
Dose-response study of a new oral bronchodilator, NAB 365 (clenbuterol).
Topics: Adult; Airway Resistance; Bronchitis; Chronic Disease; Clenbuterol; Clinical Trials as Topic; Dose-R | 1978 |
5 other studies available for clenbuterol and Chronic Disease
| Article | Year |
|---|---|
Spiropent in the treatment of reversible airways obstruction.
Topics: Adult; Asthma; Bronchitis; Child; Chronic Disease; Clenbuterol; Ethanolamines; Humans | 1982 |
Cough receptor sensitivity and bronchial responsiveness in patients with only chronic nonproductive cough: in view of effect of bronchodilator therapy.
Topics: Adult; Aged; Aged, 80 and over; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchodilat | 1994 |
[Mono- and combination therapy in chronic obstructive bronchitis. The effect of a mono- and combination therapy on total resistance in patients with chronic obstructive bronchitis].
Topics: Airway Resistance; Bronchitis; Chronic Disease; Clenbuterol; Drug Therapy, Combination; Ethylenediam | 1979 |
Spiropent (clenbuterol): another choice for patients with chronic reversible airways obstruction.
Topics: Adult; Aged; Airway Obstruction; Chronic Disease; Clenbuterol; Female; Humans; Male; Middle Aged | 1991 |
The effects of clenbuterol hydrochloride on the pulmonary function of calves with subacute and chronic bronchopneumonia.
Topics: Animals; Bronchopneumonia; Cattle; Cattle Diseases; Chronic Disease; Clenbuterol; Ethanolamines; Res | 1988 |